FONR

NEUTRAL

$18.61 Live

FONAR Corporation · NASDAQ

$12.0 52W Range $18.86

FONR FONAR Corporation - Fundamental Analysis

NEUTRAL

Console Chart News

FONR Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Diagnostics & Research

Current Price Live

$18.61

52W High

$18.86

52W Low

$12.0

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 10, 2026

Market cap

$117.26M

P/E

16.18

ROE

6.0%

Profit margin

7.1%

Debt/Equity

0.24

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

75%

FONR presents as a classic value play with a stable Piotroski F-Score of 4/9 and a current price ($18.61) trading significantly below its Graham Number ($26.43). The company maintains an exceptionally strong balance sheet with a Current Ratio of 10.00 and very low debt (D/E 0.24), providing a massive safety cushion. However, this financial stability is offset by stagnant growth metrics, with YoY earnings growth of only 1.10%, and a bearish technical trend (10/100). Ultimately, the stock appears to be a low-risk, low-reward 'value trap' unless a growth catalyst emerges.

Key Strengths

Exceptional liquidity with a Current Ratio of 10.00

Very low leverage (Debt/Equity of 0.24)

Trading at a discount to book value (P/B 0.69)

Consistent profitability in a sector where average ROE is deeply negative

Attractive valuation relative to sector P/E (16.18 vs 45.52)

Key Risks

Stagnant growth (Revenue growth of only 2.40% YoY)

Bearish technical trend (10/100 score)

Low insider sentiment (40/100)

Lack of analyst coverage and institutional visibility

Significant underperformance in growth compared to healthcare sector peers

AI Fair Value Estimate

Based on comprehensive analysis

$18.5

-0.6% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Stable Value / Growth Laggard

Key drivers: Strong Balance Sheet, Low Valuation, Anemic Growth

Confidence

80%

Value

85/100

Ref P/E 16.18, P/B 0.69, Graham Number $26.43

Positives

Price below Graham Number
P/B below 1.0
Low P/E relative to sector

Watchpoints

Intrinsic value based on growth is low ($9.95)

Future

20/100

Ref Growth rates

Positives

Slight Q/Q earnings improvement (4.7%)

Watchpoints

YoY revenue growth (2.4%) is negligible
Earnings growth (1.1%) is nearly flat

Past

60/100

Ref Historical trends

Positives

Strong 1Y price performance (+48.2%)

Watchpoints

Long-term 5Y change is minimal (+3.3%)

Health

80/100

Ref Piotroski F-Score 4/9, Current Ratio 10.00

Positives

Current Ratio of 10.00
Low Debt/Equity
Positive Profit Margins

Watchpoints

Piotroski F-Score is only moderate (4/9)

Dividend

0/100

Ref Yield N/A

Positives

No standout positives identified.

Watchpoints

No dividend payments
0% payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$18.61

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for FONR and closest competitors.

Updated 2026-04-09

Company	5Y	3Y	1Y	6M	1M	1W
FONR FONAR Corporation Primary	+3.3%	+15.4%	+48.2%	+20.1%	+0.7%	+0.1%
DH Definitive Healthcare Corp. Peer	-97.5%	-89.8%	-57.4%	-66.5%	-13.7%	-13.0%
BDSX Biodesix, Inc. Peer	-97.8%	-75.2%	-34.9%	+31.6%	+72.1%	+49.0%
EMPG Empro Group Inc. Peer	+299.1%	+299.1%	+299.1%	-2.2%	0.0%	0.0%
AGEN Agenus Inc. Peer	-93.5%	-88.0%	+124.2%	-10.7%	+36.6%	+18.4%

FON

FONAR Corporation

Primary

+3.3%

+15.4%

+48.2%

+20.1%

+0.7%

+0.1%

Definitive Healthcare Corp.

Peer

-97.5%

-89.8%

-57.4%

-66.5%

-13.7%

-13.0%

BDS

Biodesix, Inc.

Peer

-97.8%

-75.2%

-34.9%

+31.6%

+72.1%

+49.0%

EMP

Empro Group Inc.

Peer

+299.1%

-2.2%

0.0%

AGE

Agenus Inc.

Peer

-93.5%

-88.0%

+124.2%

-10.7%

+36.6%

+18.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

16.18

N/A

0.69

1.11

0.89

6.29

$117.26M

Profitability

Profit margins and return metrics

Profit Margin 7.12%

Operating Margin 11.74%

Gross Margin 40.8%

ROE 6.01%

ROA 3.16%

Growth

Revenue and earnings growth rates

Revenue Growth +2.4%

Earnings Growth +1.1%

Q/Q Revenue Growth +2.39%

Q/Q Earnings Growth +4.7%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.24

Low debt

Current Ratio

10.0

Strong

Quick Ratio

9.66

Excellent

Cash/Share

$8.1

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

37.9%

Op. Margin

11.7%

Net Margin

8.0%

Total Assets

$0.2B

Liabilities

$0.1B

Equity

$0.2B

Debt/Equity

0.31x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

-133%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14

$N/A

Healthcare Sector Comparison

Comparing FONR against 205 companies in the Healthcare sector (17 bullish, 70 neutral, 118 bearish)

P/E Ratio

16.18

This Stock

43.63

Sector Avg

-62.9% (Discount)

Return on Equity (ROE)

6.01%

This Stock

-42.45%

Sector Avg

-114.2% (Below Avg)

Profit Margin

7.12%

This Stock

-18.49%

Sector Avg

-138.5% (Weaker)

Debt to Equity

0.24

This Stock

4.76

Sector Avg

-94.9% (Less Debt)

Revenue Growth

2.4%

This Stock

106.86%

Sector Avg

-97.8% (Slower)

Current Ratio

10.0

This Stock

3.53

Sector Avg

+182.9% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
FONR FONAR Corporation	NEUTRAL	$117.26M	16.18	6.0%	7.1%	$18.61
DH Definitive Healthcare Corp.	NEUTRAL	$111.79M	-	-40.4%	-57.5%	$1.07	Compare
BDSX Biodesix, Inc.	BEARISH	$93.92M	-	-302.6%	-49.3%	$11.74	Compare
EMPG Empro Group Inc.	NEUTRAL	$143.05M	192.89	66.3%	13.7%	$17.36	Compare
AGEN Agenus Inc.	BEARISH	$144.21M	-	-%	-32.9%	$3.99	Compare

FONR FONAR Corporation

NEUTRAL

Mkt Cap

$117M

P/E

16.2

ROE

6.0%

Price

$18.61

Compare with FONR

Compare with FONR

EMPG Empro Group Inc.

Compare with FONR

Compare with FONR

Past News Coverage

Recent headlines mentioning FONR from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

FONR

FONR FONAR Corporation - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Past News Coverage

Wait — Don't Miss Out!